[
  {
    "ts": null,
    "headline": "What Biogen (BIIB)'s China Review for At‑Home LEQEMBI Injections Means For Shareholders",
    "summary": "Biogen and Eisai recently announced that Chinese regulators have accepted their Biologics License Application for a subcutaneous, at‑home injectable version of Alzheimer’s drug LEQEMBI, advancing it into formal review in China. This step could broaden access to Alzheimer’s treatment by shifting some care from hospital infusion centers to self-administered therapy, potentially easing pressure on healthcare systems in a rapidly aging market. Next, we’ll examine how the China review for at-home...",
    "url": "https://finnhub.io/api/news?id=b17483bf5cab51b97fffbc3d9d65923b9e83c02c008648c180426ed90a095e8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767791424,
      "headline": "What Biogen (BIIB)'s China Review for At‑Home LEQEMBI Injections Means For Shareholders",
      "id": 138027466,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen and Eisai recently announced that Chinese regulators have accepted their Biologics License Application for a subcutaneous, at‑home injectable version of Alzheimer’s drug LEQEMBI, advancing it into formal review in China. This step could broaden access to Alzheimer’s treatment by shifting some care from hospital infusion centers to self-administered therapy, potentially easing pressure on healthcare systems in a rapidly aging market. Next, we’ll examine how the China review for at-home...",
      "url": "https://finnhub.io/api/news?id=b17483bf5cab51b97fffbc3d9d65923b9e83c02c008648c180426ed90a095e8f"
    }
  }
]